Avodart and Acetaminophen Interaction: What the Evidence Actually Shows

Dutasteride (brand name Avodart) is an oral 5-alpha reductase inhibitor approved by the FDA for benign prostatic hyperplasia (BPH) and used off-label by some prescribers for androgenetic alopecia. Acetaminophen (paracetamol, sold as Tylenol and in many combination products) is an over-the-counter and prescription analgesic and antipyretic. These are unrelated drug classes with no shared receptor target, so the practical question is narrower than "do they interact": it is whether the two drugs' shared dependence on the liver for clearance matters for a given patient.

The direct answer

There is no established pharmacokinetic or pharmacodynamic interaction between dutasteride and acetaminophen at standard doses in patients with normal liver function. Dutasteride is metabolized primarily through hepatic CYP3A4 (and to a lesser extent CYP3A5), according to its FDA label. Acetaminophen is cleared mainly through phase II conjugation (glucuronidation and sulfation), with a smaller fraction oxidized through CYP2E1 into the reactive, potentially hepatotoxic metabolite NAPQI. Because the two drugs rely on largely separate pathways, most major drug-interaction references classify this pairing as low concern. The evidence gap is not about whether a PK interaction exists, but about how much combined hepatic burden is acceptable in patients whose liver reserve is already reduced, and that specific threshold is not defined in the dutasteride label or in any source available for this review.

How each drug is cleared, and where the pathways actually overlap

Dutasteride's FDA-approved prescribing information states that the drug is extensively metabolized by CYP3A4, with CYP3A5 playing a secondary role. Its terminal half-life is described as prolonged (on the order of weeks), which is why the label recommends caution with strong CYP3A4 inhibitors: reduced clearance can let concentrations climb over an extended period.

Acetaminophen's metabolism is well established in general pharmacology: the majority of a therapeutic dose is conjugated by UGT and sulfotransferase enzymes rather than processed by the CYP system. A minority fraction goes through CYP2E1 (with smaller contributions from CYP1A2 and CYP3A4) to form NAPQI, which is normally neutralized by hepatic glutathione. This oxidative pathway becomes clinically important only when it is upregulated (as with chronic alcohol use) or when glutathione stores are depleted (as with malnutrition, fasting, or overdose).

The overlap between the two drugs is the minor CYP3A4 contribution to acetaminophen clearance. Acetaminophen is not considered a clinically meaningful CYP3A4 inhibitor or inducer at therapeutic doses, so this overlap does not translate into a documented effect on dutasteride levels. No published pharmacokinetic study demonstrating a bidirectional interaction between these two specific drugs was located for this review, and claims citing a precise inhibition constant or percentage change in exposure should be treated as unverified until checked against the primary literature.

What is established, what is plausible, and what is not established

This is the evidence-boundary summary a reader should hold onto rather than any single number in this article.

Established: Dutasteride and acetaminophen use different primary clearance pathways (CYP3A4-dependent oxidative metabolism versus phase II conjugation). The FDA label for dutasteride advises caution in patients with liver disease, independent of any interaction with acetaminophen. Acetaminophen's own hepatotoxicity risk at supratherapeutic doses, and its increased risk with chronic alcohol use, is well documented in general hepatology and toxicology literature, and regulatory action has previously limited the acetaminophen content of prescription combination products for this reason.

Plausible but unproven: That combining dutasteride with regular, higher-dose acetaminophen use meaningfully increases hepatic stress beyond what either drug would cause alone, in patients who already have reduced hepatic reserve (fatty liver disease, chronic alcohol use, cirrhosis, or concurrent strong CYP3A4 inhibitors). This is a reasonable extrapolation from how each drug is cleared, not a finding from a dedicated interaction study.

Not established: Any specific numeric interaction magnitude between dutasteride and acetaminophen (percentage change in exposure, odds ratio for liver injury when combined, or a validated combined-dose threshold). The version of this article previously in circulation cited several precise figures, including an inhibition potency number for acetaminophen at CYP3A4, a specific liver-failure attribution percentage, an odds ratio for alcohol plus acetaminophen, and two attributed physician quotations. None of those could be verified against a checked primary source for this rewrite, so they have been removed rather than repeated. An editor with access to the primary literature should verify before any such figure is reinstated.

Evidence-status interaction assessment

Practical implications for co-administration

Dutasteride is typically dosed at 0.5 mg once daily for BPH, and that dose is not adjusted because of acetaminophen use. For acetaminophen, the FDA-recognized general adult ceiling is up to 4 g per day from all sources combined, with lower ceilings commonly recommended by clinicians for people with reduced hepatic reserve, chronic alcohol use, or advanced age. This article does not set a dutasteride-specific acetaminophen ceiling because no source reviewed here establishes one; readers with liver disease, heavy alcohol use, or multiple hepatically cleared medications should get an individualized ceiling from their prescriber or pharmacist rather than applying a number from this page.

Patients on long-term dutasteride who also take a strong CYP3A4 inhibitor (certain antifungals, some HIV protease inhibitors, some macrolide antibiotics) are the group where the dutasteride label itself flags caution. Adding acetaminophen in that setting does not create a new mechanism of harm, but it does add another hepatically cleared substance to track, which is a reasonable point to raise with a pharmacist doing a medication reconciliation.

The AASLD and other hepatology bodies have general guidance on tracking all sources of acetaminophen (cold and flu combinations, sleep aids, opioid-acetaminophen combination analgesics) in patients with any liver concern; that guidance applies to dutasteride patients with liver risk factors as a subset of the general population, not because of a dutasteride-specific interaction.

When this combination needs closer attention

A reasonable trigger for checking in with a prescriber or pharmacist, rather than continuing self-directed dosing, includes any of the following: a known diagnosis of liver disease or cirrhosis, regular alcohol use of more than one to two drinks per day, use of a strong or moderate CYP3A4 inhibitor alongside dutasteride, regular acetaminophen use beyond a few weeks, or new symptoms such as persistent nausea, right upper quadrant pain, dark urine, or jaundice. Jaundice or persistent right upper quadrant pain in anyone taking either drug warrants prompt medical evaluation rather than waiting for a routine visit, since acetaminophen-related liver injury can progress quickly once glutathione reserves are exhausted, and dutasteride's long half-life means its contribution to hepatic load does not clear quickly either.